BofA analyst Jason Gerberry raised the firm’s price target on Johnson & Johnson to $253 from $227 and keeps a Neutral rating on the shares. The firm increased its J&J out-year revenue estimates to reflect updated views on certain near-to-market pipeline assets, notably Tecvayli and Inlexzo, along with what it sees as a knock-on effect from strong Tecvayli data to Darzalex treatment duration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Balanced Outlook on Johnson & Johnson: Higher Oncology-Driven Estimates but Limited Upside Justify Hold Rating
- KURE vs. VHT: Comparing China and U.S. Healthcare ETFs
- Boeing, Walmart, Coca-Cola, Ford, J&J: Insider Moves Exposed
- J&J posts early phase 1b results for pasritamig in metastatic prostate cancer
- How JNJ, TEM, and LLY Used AI to Redefine Healthcare Compounding